| 3.85 0.32 (9.07%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.03 | 1-year : | 8.28 |
| Resists | First : | 5.16 | Second : | 7.09 |
| Pivot price | 2.85 |
|||
| Supports | First : | 2.05 | Second : | 1.71 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 2.74 |
| MA(100) : | 6.05  |
MA(250) : | 17.17 |
|
| MACD | MACD : | 0 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 29.9 |
D(3) : | 36.2 |
| RSI | RSI(14): 62.4 |
|||
| 52-week | High : | 66.59 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CVM ] has closed below upper band by 8.1%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4 - 4.02 | 4.02 - 4.04 |
| Low: | 3.26 - 3.28 | 3.28 - 3.3 |
| Close: | 3.82 - 3.85 | 3.85 - 3.88 |
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Mon, 14 Jul 2025
CEL-SCI raises $5.7 million in at-market offering of common stock - Investing.com Nigeria
Mon, 14 Jul 2025
CEL-SCI Closes $5.7 Million Stock Offering - MarketScreener
Mon, 14 Jul 2025
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules - Business Wire
Sat, 12 Jul 2025
CEL-SCI Raises $5.7M via Stock Offering at $3.82/Share - AInvest
Sat, 12 Jul 2025
CEL-SCI's Strategic Capital Allocation and Multikine Catalysts: A High-Risk, High-Reward Play - AInvest
Sat, 12 Jul 2025
CEL-SCI's $5.7M Offering: A High-Risk Gamble on Lifesaving Potential? - AInvest
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 4,490 (K) |
| Shares Short P.Month | 6,820 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -61.5 % |
| Return on Equity (ttm) | -250.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -6.64 |
| PEG Ratio | 0 |
| Price to Book value | 24.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|